Market News & Trends
Petros Pharmaceuticals Launches Two Self-Selection Studies for ED Drug
Petros Pharmaceuticals, Inc. recently initiated two self-selection studies for its erectile dysfunction (ED) drug STENDRA (avanafil). The results of these studies will be part of…
Catalent Launches New Xpress PharmaceuticsT Service to Expedite Development of Oral Drugs for Adaptive Phase 1 Clinical Trials
Catalent recently announced the launch of its new Xpress Pharmaceutics service, designed to accelerate the development of oral drugs through Phase 1 clinical studies. By integrating formulation….
CordenPharma Collaborates With PeptiSystems on Continuous Peptide Manufacturing & Green Chemistry
Due to the promising, yet underutilized potential of Green Chemistry and continuous manufacturing synthesis approaches gaining traction in the wider pharmaceutical community, CordenPharma recently announced a collaboration with PeptiSystems, a Swedish-based developer of….
HOOKIPA Announces First Patient Enrolled in Phase 2 Trial Evaluating HB-200 & Pembrolizumab for Treatment of Head & Neck Cancer & Reports FDA’s Fast Track Designation
HOOKIPA Pharma Inc. recently announced the first patient has been dosed with HB-200 in combination with pembrolizumab for the treatment of first-line advanced/metastatic Human Papillomavirus 16….
Resverlogix Announces Commencement of Patient Enrollment & Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment
Resverlogix Corp. recently announced enrollment and dosing of patients has commenced in a Phase 2b study at a site at the University of Alberta Hospital in Edmonton. The trial will evaluate the safety and efficacy of apabetalone….
Artizan Biosciences Selects Lead Product Candidate for Inflammatory Bowel Disease Therapeutic Development Program
Artizan Biosciences, Inc. recently announced the selection of its lead product candidate, ARZC-001, for the treatment of inflammatory bowel disease (IBD). Discovered internally and….
Evaxion Biotech Receives Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 in Combination with KEYTRUDA for Treatment of Melanoma
Evaxion Biotech A/S recently announced it has received clearance from the Australia Therapeutic Goods Administration to initiate a Phase 2b trial of its patient specific cancer immunotherapy EVX-01 in combination with….
BetterLife Obtains Positive In Vivo Oral Bioavailability, Food Effect & Pharmacokinetics Data for BETR-001
BetterLife Pharma Inc. recently announced it has obtained positive results from an in vivo oral bioavailability and food-effect pharmacokinetic (PK) study on BETR-001 in beagle…
Lonza, Forbion, and BioGeneration Ventures Extend Collaboration to Add Development & Manufacturing Services of Small Molecules
Forbion, a leading venture capital firm building life sciences companies, BioGeneration Ventures (BGV), its joint venture partner and specialized life sciences venture capital firm focusing…
EQRx Announces Two Lancet Oncology Publications of Positive Phase 3 Results of Sugemalimab in Stage III & Stage IV Non-Small Cell Lung Cancer
EQRx, Inc. recently announced data from its partner CStone Pharmaceuticals’ two pivotal Phase 3 studies of the anti-PD-L1 monoclonal antibody sugemalimab for the treatment of…
Clinical Trial Begins in the UK to Investigate 3-in-1 High Blood Pressure Pill
George Medicines recently announced its proprietary triple low-dose combination pill, GMRx2, will be trialed in UK patients with high blood pressure (hypertension), in a collaboration…
Evelo Biosciences Presents Data on EDP1815 Mechanism of Action & Supporting Ongoing Clinical Development for Inflammatory Diseases
Evelo Biosciences, Inc. recently announced data for EDP1815, the company’s lead product in inflammation, detailing its mechanism of action and supporting further clinical development in patients with psoriasis and atopic dermatitis…..
Imcyse Reports Positive Immune Response from Interim Analysis of Phase 2 IMPACT Type 1 Diabetes Study
Imcyse recently reported positive biomarker data from a planned interim analysis of its Phase 2 study, IMCY-0098 Proof of ACtion in Type 1 Diabetes (T1D) (IMPACT), evaluating the company’s lead candidate….
Salarius Pharmaceuticals Expands Oncology Pipeline Through Strategic Acquisition of Targeted Protein Degradation Portfolio From DeuteRx, LLC
Salarius Pharmaceuticals, Inc. recently announced a definitive agreement with DeuteRx, LLC to acquire an oral, small molecule targeted protein degradation portfolio. The acquisition includes a lead….
Rhythm Pharmaceuticals Announces First Patients Dosed in DAYBREAK & Weekly Trials Evaluating Setmelanotide for Rare Genetic Diseases of Obesity
Rhythm Pharmaceuticals, Inc. recently announced the first patient has been dosed with setmelanotide, the company’s melanocortin-4 receptor (MC4R) agonist, in the Phase 2 DAYBREAK clinical…
Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Property Portfolio
Brooklyn ImmunoTherapeutics, Inc. recently announced 18 new patents were issued and 17 new patent applications were filed in 2021. The intellectual property is owned by…
Proscia & Datavant Partner to Connect Pathology Data With Health Data Ecosystem for Life Sciences R&D
Proscia and Datavant recently announced a partnership that will provide life sciences companies with digitized pathology data to power the development of novel therapeutics and diagnostics.…
INCOG BioPharma Services Builds State-of-the-Art Facility With Promise to Deliver a Better Customer Experience
INCOG BioPharma Services is nearing completion on the construction of its manufacturing facility and global headquarters in Fishers, Indiana. The 90,000-sq-ft facility will be the…
Q-VANT Biosciences Launches to Solve the Pharmaceutical Industry Problem of Limited Quillaja Saponin-Based Adjuvants for Life-Saving Vaccines
Q-VANT Biosciences has launched as the first company to achieve a 100% sustainable way to meet the growing global vaccine market demand for Quillaja saponin-based adjuvants including QS-21. QS-21 is considered the “Gold Standard” adjuvant for enhancing immune….
HUTCHMED Receives Breakthrough Therapy Designation in China for HMPL-523 for Treatment of Primary Immune Thrombocytopenia
HUTCHMED (China) Limited recently announced the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) to HMPL-523,…
